Andrew S. Ittleman/LinkedIn
Nov 5, 2025, 05:27
Andrew S. Ittleman: Florida’s New Stem Cell Laws Raise FDA and Patient Safety Concerns
Andrew S. Ittleman, Owner at Fuerst Ittleman David & Joseph, shared on LinkedIn:
”In July, Florida passed new “stem cell therapy” laws, which allow physicians to administer allogeneic “stem cell” products to patients. Among other problems with Florida’s new stem cell laws, they (i) authorize products which FDA prohibits, (ii) do not define “stem cell,” (iii) create a risk of patient confusion.
We have decades of history to understand the potential consequences of these laws, but that history seems to have been ignored during the legislative process. I explore these issues in the article available at the link below.”
Find more information here.
Stay informed with Hemostasis Today.
-
Oct 9, 2026, 12:24Mercy Lung’aho: When Diet Quality and Nutritional Biomarkers Tell Different Stories
-
Oct 9, 2026, 12:22Eugene Fan: Bridging Therapeutic Breakthroughs and Equitable Thalassaemia Care
-
Oct 9, 2026, 12:14Brittany Busse: A New Focus on Iron Deficiency Before Anemia
-
Oct 9, 2026, 12:13Akshat Jain: A New Textbook Bringing Global Perspectives on Sickle Cell Disease
-
Oct 9, 2026, 12:03Heather Case: Bridging Awareness and Action in Women’s Hemophilia Care
-
Oct 9, 2026, 11:58Brandon Luu: Can Iron Deficiency Cause Fatigue Without Anemia?
-
Oct 9, 2026, 11:51Sumaiya Dickens: Marginal Zone B Cells in Transfusion Medicine and Hemophilia A Research
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk